Our Take
Labiotech's 200-episode run is a media business story, not a biotech breakthrough, but the founding thesis—that European life sciences deserved better storytelling—remains true and underexploited.
Why it matters
European biotech struggles for visibility and funding partly because storytelling and founder networks remain fragmented. A media platform that aggregates both is rare and competitive; watching how Eeckhout shapes the next phase signals whether integrated communication can move the needle on capital flow.
Do this week
Biotech founders and investors in Europe: audit where your team sources R&D news and sector trends this month; if it's still fragmented across journals, Twitter, and analyst reports, subscribe to one dedicated platform and measure whether it shortens your deal sourcing cycle in Q1.
From frustration to 200 episodes
Joachim Eeckhout co-founded Labiotech because he saw a gap. European life sciences lacked the coordinated storytelling infrastructure that existed in the US. He started by visiting biotech CEOs on a legendary bike tour of France, gathering stories and validating that the market opportunity was real: European biotech deserved a dedicated media and intelligence platform.
That vision became Labiotech, which grew to claim the title of Europe's largest biotech media outlet. In 2021, IN-PART acquired the platform, integrating it into a larger ecosystem designed to connect the R&D marketplace. The podcast has now reached episode 200, with Eeckhout as a returning guest to reflect on the arc.
Biotech media concentration and founder signal
Labiotech's growth and acquisition underscore a structural truth: European biotech fundraising and talent recruitment depend partly on narrative reach. Founders and researchers without a clear way to tell their story to capital, partners, and talent face friction. A dedicated platform reduces that friction.
The episode also signals that founder-led media can be acquisition-grade: IN-PART saw enough value in Labiotech's audience, editorial credibility, and network to fold it into a larger play on R&D ecosystem connectivity. That precedent matters for future science communicators deciding whether to build independent or sell early.
Use Labiotech as a benchmark for your own communication
If you lead R&D at a European biotech or a fund investing in the sector, treat Labiotech's 200-episode run and Eeckhout's candid take on the current media landscape as a master class in how storytelling compounds. The company's growth didn't come from a single hit story or founder celebrity; it came from persistence, editorial standards, and deep relationships with the European ecosystem. Ask yourself whether your own communication strategy includes regular, independent publication of your work and thinking, or whether you rely entirely on third-party coverage and paid channels. If the latter, you're playing at a disadvantage in a market where narrative trust is scarce.